Highlights from the ERS International Congress 2020 – Slide Kit
Nuove analisi su IPF, PF-ILD e SSc-ILD presentate al Congresso Internazionale ERS, 7-9 settembre 2020
Nel seguente slike kit sono riportate le principali analisi in ambito ILD presentate a ERS International Congress 2020:
IPF
- Effects of nintedanib on markers of epithelial damage in subjects with IPF: data from the INMARK® trial (Gisli Jenkins R)
- Monocyte count and decline in forced vital capacity (FVC) in patients with IPF (Tzouvelekis A)
PF-ILD
- Effects of nintedanib in patients with progressive fibrosing ILDs and differing baseline FVC: further analyses of the INBUILD® trial (Valenzuela C)
- Effects of nintedanib on progression of ILD in patients with fibrosing ILDs and a progressive phenotype: further analyses of the INBUILD trial (Flaherty KR )
- Does nintedanib have the same effect on FVC decline in patients with progressive fibrosing ILDs treated with DMARDs or glucocorticoids? (Chaudhuri N)
SSc-ILD
- Effects of nintedanib in patients with SSc-ILD and preserved and highly impaired lung function (Wuyts WA)
APPROFONDIMENTI
Highlights from the ERS International Congress
Report sulle ultime novità in ambito ILD emerse dal Congresso Internazionale ERS, 7-9 Settembre 2020
APPROFONDIMENTI
Highlights from the 6th SScWC 2020 E-Congress – slide kit
Nuove analisi dello studio clinico SENSCIS su SSc-ILD presentate al 6° SSc WC Congress, 2020
APPROFONDIMENTI
SENSCIS trial: additional analysis presented at Virtual EULAR 2020
Nuove analisi dello studio SENSCIS (Nintedanib in SSc-ILD) presentate a European League Against Rheumatism (EULAR) 2020 Virtual Congress – Slide kit
APPROFONDIMENTI
INBUILD trial: additional analysis presented at Virtual EULAR 2020
Nuove analisi dello studio INBUILD (Nintedanib in PF-ILDs) presentate a European League Against Rheumatism (EULAR) 2020 Congress – Slide kit